pharmacologically acceptable salt thereof according to claim 1 as an active ingredient.

16. The pharmaceutical composition according to claim 15 which is a PDE9 inhibitor.

17. The pharmaceutical composition according to claim 15 for increasing the intracerebral cGMP concentration.

18. A cognitive impairment improving agent in Alzheimer's disease, comprising the compound or pharmacologically acceptable salt thereof according to claim 1.

~~19. A method for improving cognitive impairment in Alzheimer's disease, comprising administering the compound or pharmacologically acceptable salt thereof according to claim 1 to a patient.~~

~~20~~19. The compound or pharmacologically acceptable salt thereof according to claim 1 for use for improving cognitive impairment in Alzheimer's disease.